DigestRedComo funciona
Red
/
Empresas
Al
No verificado

Almirall, S.A.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

11 Comunicados de prensa

Ver todos los comunicados de prensa
10/11/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado de valores
Venta al público/Minorista
Almirall’s 2025 9M Results
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0
18/09/2025
Salud
Sanidad
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 2025
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0
17/09/2025
Ciencia
Sanidad
Farmacéutica
Ir de compras
Jóvenes
Medicina - Varios
Biotecnología
Tercera edad
Salud
Eventos
Industria
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0
25/07/2025
Ciencia
Finanzas
Asociaciones/Profesionales
Biotecnología
Salud
Farmacéutica
Sanidad
Venta al público/Minorista
Eventos
Mercado de valores
Almirall H1 2025 Results
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0
12/05/2025
Almirall Q1 2025 Results
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0
07/03/2025
Multimedia
Industria
Oncología
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with Tirbanibulin
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0
06/03/2025
Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0
24/02/2025
Multimedia
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mercado de valores
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0
11/11/2024
Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0
15/10/2024
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
Fuente
Almirall, S.A.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0